Novo Nordisk's Diabetes Drug Outshines Ozempic: Buy?
A new diabetes drug from Novo Nordisk could change the GLP-1 landscape. This deep dive breaks down what investors sho...
Wondering which is better: cash back or points credit card? Explore the pros and cons to choose the right card for your needs.
27,103 articlesA new diabetes drug from Novo Nordisk could change the GLP-1 landscape. This deep dive breaks down what investors sho...
A sizable early-2026 investment in a gold-focused miner is turning heads. This article breaks down what it could mean...
AI is rewriting investing playbooks. This piece uncovers a prophetic phrase from IBM and shows how it can inform smar...
TriSalus investors are eyeing the Q1 2026 earnings update to gauge cash runway, pipeline progress, and milestone-driv...
A fresh, investor-ready look at StoneX's Q2 2026 results. This article breaks down the key numbers, what they mean fo...
Oklo faces a pivotal moment after July. This piece explains a single catalyst investors should watch, the potential s...
Investors dig into a mixed session as Amazon leads gains on Prime Day momentum and AI shopping activity. This guide b...
A sharp drop in Oddity Tech shares sparked questions about the health of a high-growth tech play. Even with solid qua...
A Berkshire-inspired ETF touts a 15% yield by layering a stock-picker approach with an option strategy and return of ...
A potential SpaceX move into retail mobile service could alter the telecom landscape. This article breaks down how St...
CoreWeave delivered stronger top-line growth but a widening loss and cautious quarterly guidance. Investors reacted w...
Rocket Lab delivers a record quarter that lights up the stock market today. This deep dive explains the rally, the ba...